Professor Ian Chi Kei Wong (黃志基)
B.Pharm(Hons) Sunderland UK, MSc, PhD Manchester UK
- Honorary Fellow of Royal College of Paediatrics and Child Health
- Fellow of Royal Pharmaceutical Society (UK) Honorary
- Fellow of College of Pharmacy Practice (HK)
- Fellow of the Higher Education Academy (England)
- Fellow of the Academy of Life Sciences for Chinese (UK)
- Registered Pharmacist (UK & HK)
- Executive Editor of British Journal of Clinical Pharmacology
- Member of International Editorial Board of Drug Safety
- Member of International Editorial Board of Pediatric Drugs
Professor Ian Wong is jointly appointed by the University of Hong Kong and UCL School of Pharmacy in London ( https://iris.ucl.ac.uk/iris/browse/profile?upi=ICKWO00 ).
Professor Wong is the Co-Director of the Centre for Safe Medication Practice and Research ( http://www.pharma.hku.hk/sweb/CSMPR/ ) at the HKU and Head of Research Department of Practice and Policy at UCL School of Pharmacy. ( http://www.ucl.ac.uk/pharmacy/departments/practice-policy ).
He was Chair of the Examination Committee and Internship Committee of the Pharmacy and Poisons Board of Hong Kong, and a member of the Grant Review Board of the Research Council of the Food and Health Bureau.
Prior to his current appointment Professor Wong was the Head of the Department of Pharmacology and Pharmacy of HKU between 2011 and 2015, the Founding Director of the Centre for Paediatric Pharmacy Research between 2002 and 2011, at The School of Pharmacy, UCL Institute of Child Health, University of London and Great Ormond Street Hospital for Children
A recipient of a UK Department of Health Public Health Career Scientist Award in 2002, Professor Wong is the only pharmacist to date to have received such an award in the UK. He also received the Chemist and Druggist's Pharmacy Practice Research Medal in 2004 for his research in paediatric medicines. In recognition of his work in paediatric medicines research, Professor Wong was awarded an Honorary Fellowship of the Royal College of Paediatrics and Child Health in 2011, and Fellowship of the Royal Pharmaceutical Society in 2012.
Professor Wong has been awarded approximately £5 million in research grants as the principal applicant and approximately £33 million as a co-applicant from the UK Medical Research Council, UK Engineering and Physical Science Research Council, UK Economic and Science Research Council, Department of Health in England, the European Commission and the pharmaceutical industry. He was also advisor to the Department of Health in England, World Health Organisation, European Medicines Agency and the pharmaceutical industry.
Professor Wong qualified as a pharmacist in 1992 and worked at the former Medicines Control Agency (Regulatory Authority) in the Yellow Card system between 1992 and 1993. His research career in medication safety began when he took up a research pharmacist post at the David Lewis Centre for Epilepsy to investigate the safety of new antiepileptic drugs between 1994 and 1997. Professor Wong received his PhD from Manchester Medical School in 1998 for his work at the David Lewis Centre. Thereafter, he took up a Lecturer in Pharmacy Practice post at the University of Bradford in 1997, and became Senior Lecturer in 2001.
Professor Wong has been an expert witness for many legal cases in the UK and Hong Kong regarding medication safety on behalf of victims of medication errors and adverse drug reactions and pharmaceutical companies.
Honours and Awards
- Chemist and Druggist Pharmacy Practice Research Conference Medal by Royal Pharmaceutical Society of Great Britain 2004.
- National Public Health Career Scientist Award by the Department of Health in England 2002.
- John M Harrison Award (Travel) by the UK College of Pharmacy Practice 1999.
My Research Interests
Medicines for Children
- Development of appropriate medicines for children
- Pharmaceutical care for children
- Medication errors
Pharmacoepidemiology and Drug Safety
- Methodological research
- Drug utilization
- Antiepileptic drugs
- ADHD treatment
- Antipsychotic drugs
Wong AYS, Root A, Douglas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, Siu DCW, Smeeth L, Wong ICK*. Cardiovascular outcomes associated with use of clarithromycin: population based study. British Medical Journal 2016; 352:h692633.
Impact Factor 17.45
Click to view:
http://www.bmj.com/content/352/bmj.h6926.long (open access)
Wong AYS, Wong ICK*, Chui CSL, Lee EHM, Chang WC, Chen EYH, Leung WK, Chan EW*. Acute neuropsychiatric events associated with Helicobacter pylori therapy containing-clarithromycin: a population-based study JAMA Internal Medicine. 2016 May 2. doi: 10.1001/jamainternmed.2016.1586. [Epub ahead of print]
Impact factor 15.04
Chui CSL, Chan EW, Wong AYS, Root A, Douglas IJ, Wong IC*. Association between oral fluoroquinolones and seizures: a self-controlled case series study. Neurology 2016 Apr 6. pii: 10.1212/WNL.0000000000002633. [Epub ahead of print] Impact Factor 8.29
Chan EW, Lau WCY, Leung WK, Mok MTC, He Y, Tong TSM, Wong ICK*. Prevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology 2015;149(3):586-595.
Impact Factor 16.72
Contribution to The National Institute for Health and Care Excellence (NICE) reports:
Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release The National Institute for Health and Care Excellence (NICE) advice [ESNM70] Published date: March 2016 (https://www.nice.org.uk/advice/esnm70/chapter/key-points-from-the-evidence)
Guidance on The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. The National Institute for Health and Care Excellence (NICE) 2012. (https://www.nice.org.uk/guidance/cg137)
Guidance on Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. The National Institute for Health and Care Excellence (NICE). 2009. (http://publications.nice.org.uk/attention-deficit-hyperactivity-disorder-cg72)
Professor Wong is the Founder and a Director of Therakind Ltd
Since Nov 2006
- In association with UCL School of Pharmacy, UCL Institute Child Health and Great Ormond Street Children’s Hospital and IPSO Ventures Professor Wong set up Therakind Ltd.
- Therakind is a commercial research organisation which works exclusively in paediatric drug research.
- The first product (Buccolam®) was granted the first “Paediatric Use Marketing Authorisation” under the new European regulation at the beginning of 2012.
- The second product (Ayendi®) was granted a product license by the Medicines and Healthcare products Agency in 2014.
- Bielicki JA, Barker CIS, Saxena S, Wong ICK, Long PF, Sharland M. Not too little, not too much: problems of selecting oral antibiotic dose for children. British Medical Journal 2015 Nov 3;351:h5447. doi: 10.1136/bmj.h5447. Impact Factor 17.45
- Man KKC, Tong HHY, Chan EW, Wong LYL, Wong ICK*. Exposure to Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Autism Spectrum Disorder in Children: A Systematic Review and Meta-analysis of Observational Studies. Neuroscience & Biobehavioral Reviews. 2015;49:82-9. Impact Factor 8.802
- Cheung CL, Sing CW, Tang C, Cheng V, Pirmohamed M, Choi CH, Hung CS, Lau EF, Lee KF, Mak MH, Leung J, Wong TW, Ho A, Chan KW, Hung V, Tam V, Siu SC, Pang HK, Wat WM, Lee HY, Chung CT, Hue RM, Sham PC, Cheung B, Wong I, Tan K, Kung A. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther. 2016 May;99(5):555-61. doi: 10.1002/cpt.309. Epub 2016 Jan 12. Impact Factor 7.903
- Lai EC, Man KK, Chaiyakunapruk N, Cheng CL, Chien HC, Chui CS, Dilokthornsakul P, Hardy NC, Hsieh CY, Hsu CY, Kubota K, Lin TC, Liu Y, Park BJ, Pratt N, Roughead EE, Shin JY, Watcharathanakij S, Wen J, Wong IC, Yang YH, Zhang Y, Setoguchi S. Report: Databases in the Asia-Pacific Region: The Potential for a Distributed Network Approach. Epidemiology. 2015 Nov;26(6):815-20. doi: 10.1097/EDE.0000000000000325. Impact Factor 6.196
- He Y, Chan EWY, Leung WK, Anand S, Wong ICK*. Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2015;41(12):1246-55. Impact Factor 5.727
- Tsoi MF, Cheung CL, Cheung TT, Wong ICK, Kumana CR, Tse HF, Cheung BMY. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Scientific Reports 2015 Aug 17;5:13204. Impact Factor 5.578
- Man KKC, Chan EW, Coghill DR, Douglas IJ, Ip P, Leung LP, Tsui MSH, Wong WHS, Wong ICK*. Methylphenidate and the Risk of Trauma. Pediatrics 2015;135(1):40-8. Impact Factor 5.473
- Chan PH, Huang D, Hai JJ, Li WH, Yin LX, Chan EW, Wong IC, Lau CP, Chiang CE, Zhu J, Tse HF, Siu CW. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm. 2016 Feb;13(2):366-73. doi: 10.1016/j.hrthm.2015.09.015. Epub 2015 Sep 21. Impact Factor 5.076
- Chan EW, Lau WC, Siu CW, Lip GY, Leung WK, Anand S, Man KK, Wong IC. The Impact of Suboptimal Anticoagulation Treatment with Antiplatelet Therapy and Warfarin on Clinical Outcomes among Patients with Non-Valvular Atrial Fibrillation: A Population-Wide Cohort Study. Heart Rhythm*. 2016 Mar 28. pii: S1547-5271(16)30150-3. doi: 10.1016/j.hrthm.2016.03.049. [Epub ahead of print] Impact Factor 5.076
* Corresponding author
Selected Successful External Grants in Hong Kong:
- Wong ICK, Cheung L, Pirmohamed M, Carlton B, Sham PC, Chan CYJ, Cheung BMY. Pharmacogenomics Assessment of Serious Cutaneous Adverse drug reactions (PASCA). Health and Medical Research Fund Department of Health Hong Kong (HK$910,000) 2014-2016.
- Wong ICK, Douglas I, Ip P, Wong WWS, Coghill D. ADHD Treatments and Hospital Accident and emergency attendance aNalysis (ATHAN). Research Grant Council. Hong Kong Government (HK$308,855) 2013-2014.
- Wong ICK, McGhee S, Tse VC, Kwan M, Wong C, Ip D, Chui J. Mother's preferences and willingness to pay for human papillomavirus vaccination for their daughters: a discrete choice experiment in Hong Kong. Health and Medical Research Fund Department of Health Hong Kong (HK$ 378,040) 2013-2015
- Wong ICK, Deferiprone Evaluation in Paediatrics (DEEP) HK$200,000 (20,000€) European Commission FP7 grant via Universitätsklinikum Erlangen. 2011 -2014
- Wong ICK, Global Research in Paediatrics (GRiP) HK$ 500,000 (50,000€) European Commission FP7 grant via University College London 2011 – 2015
- Yuen VMY, Cheuk KLD, Lam WWM, Hui WCT, ICK Wong, Irwin MG. Comparison of oral chloral hydrate and intranasal dexmedetomidine for sedation in children undergoing computerized tomography. Health and Medical Research Fund, Department of Health Hong Kong (HK$ 755,840) 2013-2014.
- Lam MPS, Cheung BMY, Wong ICK. An evaluation of the prescribing appropriateness of Hong Kong elderly and the prevalence of preventable drug related admissions to hospital. Health and Medical Research Fund, Department of Health Hong Kong (HK$ 69,990) 2013.
- Wong ICK, Chan EWY. Scoping exercise: Pharmaceutical Services of Elderly Patients in Hong Kong. Pharmaceutical Society of Hong Kong. (HK$ 70,000) 2012-2013.
- Wong ICK. Impact of Prevenar on the burden of disease due to otitis media in children. St George's Medical School London. (HK$470,000) 2011-2012.
- Wong ICK, Lam JKW. Feasibility study of transmucosal formulation of a paediatric medication. Jacobson Pharmaceutical Company. 2012-2013 (HK$180,000).
- Wong ICK, Chan EWY. Feasibility study of HerbMiners Database. HerbMiners. (HK$120,000) 2012-2013.
- Chan EW, Worsley A, Wong ICK. Pharmacoepidemiology and pharmacoeconomics of oral anticoagulation therapy in Hong Kong. Pfizer and BMS Pharmaceuticals. (HK$ 898,698) 2013-2014
- Chan EW, Wong ICK. Young adult patient experiences in the clinical management of ADHD in Hong Kong. Johnson & Johnson (HK) Ltd (HK$300,000) 2013-2014.
- Institute of Child Health, University College London. Professor Deborah Christie, Professor Alastair Sutcliffe and Professor Russell Viner.
- Institute of Psychiatry, King’s College London. Professor Emily Simonoff.
- Global Research in Pediatrics (GRIP) European Network of Excellence.
- Asian Pharmacoepidemiology Network (AsPEN).
- Attention deficit/hyperactivity disorder drugs use chronic effects (ADDUCE) Consortium
Seeking PhD candidates
We are seeking highly organised and motivated PhD candidates for research in the areas of medication safety, pharmacoepidemiology and pharmaceutical care in children and the elderly. Candidates with a background in healthcare may have an advantage, however it is not a requirement. For further information, please email Prof Ian Wong with your CV (email: email@example.com).
Selected media releases and communications
Treatment of psychiatric illness:
(Oriental Daily Chinese)
(Apple Daily Chinese)
(BBC Website English)
(BBC Website English)
(Guardian Newspaper English)
(Guardian Newspaper English)
(BBC website English)
Public seminar on immunization:
2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China